A5073197753- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical Economics and Policy
- Economic and Financial Impacts of Cancer
- Biomedical Ethics and Regulation
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Biochemical and Molecular Research
- Cancer Immunotherapy and Biomarkers
- Glutathione Transferases and Polymorphisms
- Pharmacogenetics and Drug Metabolism
- Healthcare Systems and Practices
- HER2/EGFR in Cancer Research
- Oral health in cancer treatment
- Chronic Lymphocytic Leukemia Research
- Head and Neck Cancer Studies
- Prostate Cancer Treatment and Research
- Brain Metastases and Treatment
- Ovarian cancer diagnosis and treatment
- Biosimilars and Bioanalytical Methods
- Lung Cancer Treatments and Mutations
- Clinical practice guidelines implementation
- Cancer therapeutics and mechanisms
Groupe Hospitalier Mutualiste de Grenoble
2017-2024
Agence Nationale de Sécurité du Médicament et des Produits de Santé
2018-2023
Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail
2022
Agence Nationale de la Recherche
2021
Association Française de Normalisation
2017
Karolinska Institutet
2013
Clinique Pasteur
2000-2003
Stockholm University College of Music Education
2001
Sorbonne Université
1994-1999
Pitié-Salpêtrière Hospital
1998-1999
Decisions on market authorization (MA) and reimbursement have different durations across countries because of health technology assessment (HTA) procedures negotiations between manufacturers national authorities. To overcome this delay, France has implemented a Temporary Authorization for Use (ATU) program that allows early access to drugs before MA, in order treat patients with unmet medical needs. The objectives our study were establish the added therapeutic benefit (ATB) ATUs solid tumors...
IntroductionThe cancer incidence continues to rise worldwide. Medical innovation has a major impact on patient survival, but within drug development, it can take more than 10 years obtain marketing authorisation (MA). The time required for access therapeutic remains critical, so France developed specific expanded program named ATU, which allows the administration of drugs before European Medicines Agency (EMA) approval. purpose this study is put in perspective average antineoplastic...
Shortages of drugs and medical devices have tended to increase in France worldwide, with consequences for patients healthcare professionals. Preventing shortages health products has become a priority regulatory authorities, including the French National Agency Medicines Health Products Safety (ANSM). To highlight perspectives better prevention, we described analyzed management availability over last 10 years. The supply chain was mapped identify main causes stakeholders involved managing...
This study was designed to assess the results of protracted courses ESHAP (etoposide, cyt-arabine, cisplatin, methylprednisolone) therapy followed by intensive chemotherapy and hematopoietic cell transplantation (IC+HCT) for relapsed or refractory non-Hodgkin's lymphoma (NHL). Treatment consisted 3 cycles ESHAP; responsive patients (pts) then received more cycles, IC+HCT used pts in maintained partial (PR) complete (CR) remission after sixth ESHAP. Sixty-five entered study. At enrollment, 27...
Abstract Background. Head and neck squamous cell carcinomas (HNSCC) present variable aggressiveness chemosensitivity. Because the glutathione (GSH) system thymidylate synthase (TS) are involved in resistance to main drugs used HNSCC (cisplatin 5‐FU), we studied these systems tumors normal mucosae. Methods. Tumor samples adjacent mucosae were collected from 37 untreated patients. GSH S‐transferase (GST) activity assayed by spectrophotometry, whereas TS folates determined radioassays. Results....
OPINION article Front. Pharmacol., 28 April 2021Sec. Drugs Outcomes Research and Policies https://doi.org/10.3389/fphar.2021.635841
Dihydropyrimidine dehydrogenase (DPD), the initial and rate-limiting enzyme in pyrimidine catabolism, has recently been purified to homogeneity from several species. In present study molecular cloning of DPD with isolation a cDNA coding for bovine liver is reported using polymerase chain reaction (PCR) methodology. Known amino acid sequence was used initially design mixed oligonucleotide primers amplification fragment (65 base pairs). Specific were subsequently designed utilized full-length...
The arrival of immunotherapies and targeted therapies challenged the authorities to make them available as soon possible. France has effective tools, such clinical trials (CTs) a national early access program (temporary authorizations for use [ATUs] temporary recommendations [RTUs]), allowing innovative drugs, whether or not they have been authorized used off-label, cases that reached therapeutic impasse.The methodology involved real-time data collection from ATUs, RTUs (between September 1,...
A phase I-II study was initiated in February 1991 of concomitant radiation and cisplatin (CDDP) the treatment unresectable head neck squamous cell carcinomas (n = 12). The first patient treated palliatively for a cervical recurrence laryngeal cancer. 11 other patients had locally advanced (stage IV) previously untreated oropharynx 9), hypopharynx 1), or node with unknown primary site 1). Standard external carried out up to total dose 60 Gy/6 weeks (7 MeV electron beam) 72 Gy/8 (Co60...